Quemliclustat - Arcus Biosciences
Alternative Names: AB-680; HY-125286; Quemli; Small molecule CD73 inhibitor - Arcus BiosciencesLatest Information Update: 29 Sep 2026
At a glance
- Originator Arcus Biosciences
- Developer Arcus Biosciences; Gilead Sciences; Taiho Pharmaceutical; UCLAs Jonsson Comprehensive Cancer Center
- Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Fluorobenzenes; Phosphonic acids; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action 5-nucleotidase inhibitors
-
Orphan Drug Status
Yes - Pancreatic cancer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Adenocarcinoma
- Phase II Cholangiocarcinoma; Gastrointestinal cancer; Non-small cell lung cancer
- Phase I/II Colorectal cancer
- Preclinical Malignant-mesothelioma
- No development reported Cancer
- Discontinued Prostate cancer
Most Recent Events
- 29 Sep 2026 Arcus Biosciences completes a phase I trial in Adenocarcinoma (Combination therapy, First line therapy, Late-stage disease, Metastatic disease) in USA (IV) (NCT04104672)
- 29 Sep 2026 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy) in Japan (Parenteral) prior to September 2026 (Taiho Pharmaceutical pipeline, September 2026)
- 07 Sep 2026 Arcus Biosciences completes a phase II EDGE-Gastric trial in Gastrointestinal cancer (Combination therapy, Inoperable/Unresectable, First-line therapy, Metastatic disease, Late-stage disease; Second-line therapy or greater) in the US, Canada, Chile, France, Serbia and South Korea (IV) (NCT05329766)